QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ELV

QT69Elevance Health Inc.
NYSE·Healthcare·Medical - Healthcare Plans·USA
Latest market price
388.50
-2.77-0.71%
OverviewShort InterestFilings
ELVQT69Elevance Health Inc.·NYSE
OverviewShort InterestFilings
388.50-0.71%
TA
Loading chart...
Screen all →
UNH+0.36%$400.96CVS-0.85%$98.32CI-2.04%$279.27HUM-0.37%$360.65CNC+0.63%$61.02MOH-0.08%$195.37OSCR+0.46%$28.40ALHC+2.05%$21.86
Snapshot
Index-P/E16.46EPS (ttm)23.51
Insider Own0.35%
Shs Outstand217.16M
Perf Week-2.68%
Market Cap84.97BForward P/E13.29EPS next Y29.24Insider Trans0.00%Shs Float-Perf Month-3.42%
Enterprise Value107.15BPEG-EPS next Q6.17Inst Own-Short Float-Perf Quarter33.44%
Income5.17BP/S0.42EPS this Y14.20%Inst Trans-Short Ratio-Perf Half Y10.40%
Sales200.40BP/B1.97EPS next Y8.90%ROA4.17%Short Interest-Perf YTD10.83%
Book/sh202.81P/C11.34EPS next 5Y14.72%ROE11.95%52W High426.97 -9.01%Perf Year3.55%
Cash/sh163.76P/FCF13.17EPS past 3/5Y-ROIC7.91%52W Low273.71 41.94%Perf 3Y-
Dividend Est.6.86 (1.77%)EV/EBITDA12.02Sales past 3/5Y8.34% 10.32%Gross Margin23.16%Volatility1.59% 1.77%Perf 5Y-
Dividend TTM6.86 (1.77%)EV/Sales0.53EPS Y/Y TTM19.86%Oper. Margin3.81%ATR (14)10.81Perf 10Y-
Dividend Ex-DateJun 10, 2026Quick Ratio1.48Sales Y/Y TTM13.35%Profit Margin2.62%RSI (14)47.35Recom2.31
Dividend Gr. 3/5Y10.14% 12.47%Current Ratio1.48EPS Q/Q5.10%SMA20-2.72%Beta0.38Target Price415.19
Payout28.97%Debt/Eq0.73Sales Q/Q2.64%SMA503.71%Rel Volume2.02Prev Close391.27
Employees104,200LT Debt/Eq0.72EarningsJul 16SMA20013.86%Avg Volume1.74MPrice388.50
IPO DateOct 30, 2001Option/ShortYes / YesEPS/Sales Surpr.17.79% 2.68%Net Debt/EBITDA2.49Volume3,502,292Change-0.71%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-08-26ReiteratedMizuho Securities$435 → $465
Jun-04-26ReiteratedMorgan StanleyEqual Weight$352 → $404
Jun-01-26ReiteratedTruist Financial$375 → $450
May-26-26ReiteratedBarclaysOverweight$408 → $480
May-22-26ReiteratedUBSBuy$400 → $460
May-20-26ReiteratedMizuho Securities$385 → $435
May-20-26UpgradeDeutsche BankHold → Buy$332 → $498
Apr-29-26UpgradeB of A SecuritiesNeutral → Buy
Apr-24-26ReiteratedGuggenheimBuy$396 → $399
Apr-24-26ReiteratedBarclaysOverweight$393 → $408
Latest News
Jun-17-26
Jun-17-2602:00PM
Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment NationwideYahoo
10:03AM
Elevance Health Invests $640M In Affordable Housing Over The Past Five Years, Building On More Than $1B Invested Over Nearly Two DecadesBenzinga
Jun-16-26
Jun-16-2603:44PM
Why Did UnitedHealth Stock Choose Pain Over Growth?Yahoo
Jun-15-26
Jun-15-2602:00PM
Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized SupportYahoo
01:08PM
1 Unpopular Stock That Deserves Some Love and 2 Facing ChallengesYahoo
Jun-11-26
Jun-11-2608:49AM
1 Mooning Stock Worth Your Attention and 2 We IgnoreYahoo
08:49AM
1 Mooning Stock Worth Your Attention and 2 We IgnoreYahoo
08:22AM
Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
08:22AM
Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Jun-10-26
Jun-10-2602:58PM
Forget AI: Legendary Value Investor Seth Klarman Likes This Heathcare Stock in 2026Yahoo
02:58PM
Forget AI: Legendary Value Investor Seth Klarman Likes This Heathcare Stock in 2026Yahoo
06:33AM
Elevance Health expects FY2026 GAAP EPS of at least $19.85 per share; Reaffirms Adj EPS of at least $26.75 per share.Benzinga
06:33AM
Elevance Health expects FY2026 GAAP EPS of at least $19.85 per share; Reaffirms Adj EPS of at least $26.75 per share.Benzinga
Jun-08-26
Jun-08-2601:35PM
Mizuho Maintains Outperform on Elevance Health, Raises Price Target to $465Benzinga
01:35PM
Mizuho Maintains Outperform on Elevance Health, Raises Price Target to $465Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue200,415199,125176,810
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A153,989148,223127,567
Gross Profit46,42650,90249,243
Selling, General and Administrative Excl. Other
6,33000
Research and Development
000
Other Operating Expense32,46442,79040,355
Operating Income7,6328,1128,888
Interest Expense1,4151,4021,185
Unusual Expense
———
Non-Operating Income (Expense)00-201
Net Income Before Taxes6,2176,7107,904
Income Taxes9801,0491,933
Consolidated Net Income5,2435,6625,980
Net Income From Continuing Operations5,2375,6615,971
Net Income5,2435,6625,980
EPS (Recurring)23.5125.1825.81
EPS (Basic, Before Extraordinaries)23.5125.1825.81
EPS (Diluted)23.5125.1225.68
EBITDA8,9179,65810,482
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio16.5213.96—
Price To Sales Ratio0.430.39—
Gross Margin23.1625.5627.85
Operating Margin3.814.075.03
Net Margin2.622.843.38
Shares Outstanding221222233
Market Capitalization85,85977,822—
Operating Lease Expense
———
Insider Trading Volume
$408.73$364.89$321.06$277.22$233.38● Close Price0.00M0.61M1.22M1.83M2.44MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Penczek Ronald WCAO & ControllerJun 12 '26Sale403.16369148,7663,740Jun 15 12:00 AM
Dixon Robert L JRDirectorJun 11 '26Sale401.7715160,66710,734Jun 12 12:00 AM
Penczek Ronald WCAO & ControllerMay 19 '26Option Exercise294.303,062901,1585,640May 20 12:00 AM
Penczek Ronald WCAO & ControllerMay 19 '26Sale403.131,531617,1924,109May 20 12:00 AM
SCHULMAN AMY WDirectorMar 12 '26Sale287.50267,475218Mar 23 12:00 AM
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09 12:00 AM
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06 12:00 AM
DeVore Susan D.DirectorAug 19 '25Buy312.151,200374,5803,502Aug 21 12:00 AM
BOUDREAUX GAILPresident and CEOJul 18 '25Buy286.948,5002,438,951151,020Jul 18 12:00 AM
Kaye MarkEVP & CFOApr 24 '25Sale424.824,5881,949,07418,977Apr 25 12:00 AM
Penczek Ronald WCAO & ControllerMar 10 '25Sale415.13443183,9031,847Mar 11 12:00 AM
Kendrick Charles Morgan JREVP & President, CommercialMar 05 '25Sale396.303,5041,388,63510,116Mar 05 12:00 AM
Kendrick Charles Morgan JREVP & President, CommercialOct 18 '24Sale432.147,4173,205,1828,423Oct 18 12:00 AM
PERU RAMIRO GDirectorAug 05 '24Sale531.52753400,2358,744Aug 06 12:00 AM
BOUDREAUX GAILPresident and CEOJul 22 '24Sale500.9834,00017,033,395126,709Jul 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR